Ardelyx™ was founded in 2007 by Dominique Charmot, Ph.D., Peter Schultz, Ph.D. and Jean Frechet, Ph.D., to develop a pipeline of next generation non and minimally-absorbed small molecule drugs. Through a radical approach to drug discovery and development, Ardelyx has established a pipeline of novel, first-in-class drugs engineered to correct mineral metabolism imbalance and metabolic disorders. These molecules, each of which has a unique mechanism of action, have been designed to modulate the function of specific transporters, channels, and receptors located on the epithelia (cells that line the surface) of the gastrointestinal (GI) tract. A key attribute to the design of these drugs is that their systemic exposure is greatly restricted. This attribute reduces much of the risk of side effects that stifles the development of traditionally designed drugs. As a result, we enhance the safety of our drugs and, by extension, dramatically increase the probability of regulatory and commercial success. Our products target chronic diseases affecting large populations, including hypertension, chronic kidney disease (CKD), diabetes, irritable bowel syndrome and other disorders. In short, the targeted therapeutic activity of our drugs, coupled with their minimal systemic exposure, enables Ardelyx to establish a clear pathway for the rapid, cost-effective clinical development of novel therapeutics.
Company Growth (employees)
Fremont, US
Size (employees)
93 (est)+53%
Ardelyx was founded in 2007 and is headquartered in Fremont, US

Ardelyx Office Locations

Ardelyx has an office in Fremont
Fremont, US (HQ)
34175 Ardenwood Blvd

Ardelyx Data and Metrics

Ardelyx Financial Metrics

Ardelyx's revenue was reported to be $24 m in FY, 2016
Numbers are in $, USD

Revenue (FY, 2016)

24 m

Net income (FY, 2016)

(112.4 m)

EBIT (FY, 2016)

(112.9 m)

Market capitalization (25-May-2017)

234.6 m

Closing share price (25-May-2017)


Cash (31-Dec-2016)

74.6 m
Ardelyx's current market capitalization is $234.6 m.
Numbers are in $, USDFY, 2014FY, 2015FY, 2016


24 m24 m

Revenue growth, %

R&D expense

94.2 m

General and administrative expense

18.7 m

Operating expense total

53.4 m112.9 m


(29.4 m)(112.9 m)

EBIT margin, %


Pre tax profit

(112.4 m)

Income tax expense

29 k

Net Income

(3.2 m)(29.6 m)(112.4 m)
Numbers are in $, USDFY, 2014FY, 2015FY, 2016


107.3 m107 m74.6 m

Accounts Receivable

2.6 m2.6 m


1.2 m5 m3.2 m

Current Assets

111.1 m112 m204 m


2.1 m4.7 m9 m

Total Assets

113.4 m116.9 m213.1 m

Accounts Payable

3.1 m2.8 m5.6 m

Current Liabilities

21.5 m7.7 m19.2 m

Additional Paid-in Capital

132.5 m210.4 m407.1 m

Retained Earnings

(71.9 m)(101.5 m)(213.9 m)

Total Equity

108.9 m193.2 m

Financial Leverage

1.1 x1.1 x
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Net Income

(3.2 m)(29.6 m)(112.4 m)

Depreciation and Amortization

302 k829 k1.3 m

Accounts Receivable

3.9 m2.6 m2.6 m


(2.3 m)

Accounts Payable

831 k(371 k)2.1 m

Cash From Operating Activities

13.4 m(282 k)(92.5 m)

Purchases of PP&E

(1.9 m)(3.5 m)(4.9 m)

Cash From Investing Activities

(1.9 m)(3.5 m)(131.1 m)

Cash From Financing Activities

61.3 m75 m191.2 m

Income Taxes Paid

160 k69 k69 k
Y, 2016

Financial Leverage

1.1 x

Ardelyx Market Value History

Ardelyx Company Life and Culture

You may also be interested in